Stemline Therapeutics to Present SL-801 Phase 1 Data at Upcoming ESMO Congress
August 30 2017 - 6:10PM
Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage
biopharmaceutical company developing novel therapeutics for
difficult to treat cancers, announced today that data from SL-801’s
ongoing Phase 1 trial in patients with advanced solid tumors has
been selected by the European Society of Medical Oncology (ESMO)
for poster presentation at their Annual Congress 2017, to be held
September 8-12, 2017 in Madrid, Spain. SL-801 is a novel, potent
and reversible Exportin-1 (XPO1) inhibitor.
Details on the presentation are as follows:
Title: |
|
|
Ongoing
Phase 1 Trial of SL-801, a Novel XPO-1 Inhibitor, in Patients with
Advanced Solid Tumors; Interim Results |
First Author: |
|
|
Judy Wang,
MD; Florida Cancer Specialists & Research Institute |
Abstract: |
|
|
406P
|
Date/Time: |
|
|
Monday,
September 11, 2017 – 1:15-2:15 PM CET |
Location: |
|
|
Hall
8 |
|
|
|
|
About Stemline Therapeutics Stemline
Therapeutics, Inc. is a clinical stage biopharmaceutical company
developing novel therapeutics for difficult to treat cancers.
SL-401 was granted Breakthrough Therapy Designation (BTD) for the
treatment of patients with blastic plasmacytoid dendritic cell
neoplasm (BPDCN). SL-401 is a targeted therapy directed to the
interleukin-3 receptor (CD123), a cell surface receptor
overexpressed on BPDCN and a variety of other malignancies. A
pivotal Phase 2 trial with SL-401 in BPDCN has completed enrollment
in Stages 1, 2 and 3 of the trial. An additional cohort, Stage 4,
is currently enrolling BPDCN patients to ensure ongoing access to
SL-401. Additional Phase 1/2 trials with SL-401, as a single agent
or in combination with other agents, are ongoing in patients with
other malignancies including myeloproliferative neoplasms (MPN)
(focused on chronic myelomonocytic leukemia [CMML] and
myelofibrosis [MF]), acute myeloid leukemia (AML), and multiple
myeloma. A Phase 1 trial of SL-801, a novel oral small molecule
reversible XPO1 inhibitor, is enrolling patients with advanced
solid tumors. A Phase 2 trial of SL-701, an immunotherapeutic, has
completed dosing of patients with second-line glioblastoma and
patients are being followed for outcomes including survival.
Forward-Looking Statements Some of the
statements included in this press release may be forward-looking
statements that involve a number of risks and uncertainties. For
those statements, we claim the protection of the safe harbor for
forward-looking statements contained in the Private Securities
Litigation Reform Act of 1995. The factors that could cause our
actual results to differ materially include: the success and timing
of our clinical trials and preclinical studies for our product
candidates, including site initiation, institutional review board
approval, scientific review committee approval, patient accrual,
safety, tolerability and efficacy data observed, and input from
regulatory authorities including the risk that the FDA or other
ex-U.S. national drug authority ultimately does not approve any of
our product candidates; our plans to develop and commercialize our
product candidates; market acceptance of our products;
reimbursement available for our products; our available cash and
investments; our ability to obtain and maintain intellectual
property protection for our product candidates; our ability to
manufacture; the performance of third-party manufacturers, clinical
research organizations, clinical trial sponsors and clinical trial
investigators; and other risk factors identified from time to time
in our reports filed with the Securities and Exchange Commission.
Any forward-looking statements set forth in this press release
speak only as of the date of this press release. We do not intend
to update any of these forward-looking statements to reflect events
or circumstances that occur after the date hereof.
Contact
Investor Relations
Stemline Therapeutics, Inc.
750 Lexington Avenue
Eleventh Floor
New York, NY 10022
Tel: 646-502-2307
Email: investorrelations@stemline.com
Stemline Therapeutics (NASDAQ:STML)
Historical Stock Chart
From Mar 2024 to Apr 2024
Stemline Therapeutics (NASDAQ:STML)
Historical Stock Chart
From Apr 2023 to Apr 2024